Streetbeat News

LNSR

LENSAR, Inc.

https://www.lensar.com

Industry

Medical - Devices

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.

Open

7.56

Mkt cap

88M

Volume

26K

High

7.78

P/E Ratio

-5.17

52-wk high

8.17

Low

7.45

Div yield

N/A

52-wk low

2.25

Several stocks are experiencing significant pre-market trading movements. AgileThought, Inc. (AGIL), Digital Brands Group, Inc. (DBGI), NanoVibronix, Inc. (NAOV), Tingo Group, Inc. (TIO), Top KingWin Ltd. (TCJH), Aravive, Inc. (ARAV), 1847 Holdings LLC (EFSH), Dermata Therapeutics, Inc. (DRMA), Arcadia Biosciences, Inc. (RKDA), and Globalstar, Inc. (GSAT) are among the gainers. Outlook Therapeutics, Inc. (OTLK), FibroGen, Inc. (FGEN), MasterCraft Boat Holdings, Inc. (MCFT), Ambarella, Inc. (AMBA), Genius Group Limited (GNS), TD Holdings, Inc. (GLG), Tivic Health Systems, Inc. (TIVC), VAALCO Energy, Inc. (EGY), LENSAR, Inc. (LNSR), and OKYO Pharma Limited (OKYO) are among the losers.

Portfolio Pulse from Lisa Levin

August 30, 2023 | 1:14 pm

During Wednesday's pre-market session, several healthcare stocks experienced significant movements. NanoVibronix, Aravive, Dermata Therapeutics, AEON Biopharma, Akso Health Group, and Harvard Bioscience saw increases in their stock prices, while Outlook Therapeutics, FibroGen, OKYO Pharma, Tivic Health Systems, LENSAR, and Acorda Therapeutics experienced decreases.

Portfolio Pulse from Benzinga Insights

August 30, 2023 | 1:06 pm

LENSAR (NASDAQ:LNSR) reported Q2 losses of $(0.81) per share, missing the analyst consensus estimate of $(0.35) by 131.43%. This is a 20.9% decrease over losses from the same period last year. However, the company's quarterly sales of $12.01 million beat the analyst consensus estimate of $10.00 million by 20.12%, marking a 49.44% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 11:19 am

During Friday's pre-market session, several healthcare stocks experienced significant movement. Fresh Tracks Therapeutics (FRTX), Quoin Pharmaceuticals (QNRX), LENSAR (LNSR), T2 Biosystems (TTOO), Emergent BioSolutions (EBS), and Qualigen Therapeutics (QLGN) saw increases in their stock prices. Conversely, Biofrontera (BFRI), Mirati Therapeutics (MRTX), MSP Recovery (LIFW), Ainos (AIMD), Kiora Pharmaceuticals (KPRX), and Eliem Therapeutics (ELYM) experienced declines.

Portfolio Pulse from Benzinga Insights

July 21, 2023 | 1:06 pm

During Thursday's pre-market session, several health care stocks experienced significant movements. T2 Biosystems, Pasithea Therapeutics, LENSAR, Intelligent Bio Solutions, Nanobiotix, and BioSig Technologies saw increases in their stock prices, while Vir Biotechnology, Durect, Aspira Womens Health, Cosmos Health, Gossamer Bio, and Synlogic experienced declines.

Portfolio Pulse from Benzinga Insights

July 20, 2023 | 1:06 pm

During Thursday's intraday session, several health care stocks experienced significant price movements. Gainers included ThermoGenesis Holdings, GT Biopharma, AcelRx Pharmaceuticals, CVRx, Navidea Biopharmaceutical, and LENSAR. Losers included Precipio, First Wave BioPharma, Kezar Life Sciences, Eloxx Pharmaceuticals, Coeptis Therapeutics, and PolarityTE.

Portfolio Pulse from Benzinga Insights

June 08, 2023 | 5:32 pm

LENSAR (LNSR) entered into a securities and purchase agreement with NR-GRI LP on May 12, according to a 13D filing by North Run Capital.

Portfolio Pulse from Happy Mohamed

May 19, 2023 | 12:17 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.